Veracyte VCYT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $364.23M+51.4% | $240.63M+10.7% | $217.33M+40.2% | $155M-10.9% | ||
| $44.66M-4.0% | $46.53M+15.2% | $40.38M-8.3% | $44.02M+6.2% | ||
| $488.38M+31.2% | $372.27M+30.3% | $285.62M+14.9% | $248.64M+2.3% | ||
| $22.19M-3.3% | $22.95M+11.5% | $20.58M+16.3% | $17.7M+17.2% | ||
| $767.15M+2.9% | $745.8M+6.1% | $702.98M+1.0% | $695.89M-1.7% | ||
| $82.95M-18.9% | $102.3M+15.5% | $88.59M-49.3% | $174.87M-13.7% | ||
| $50.31M— | —— | —— | —— | ||
| $1.41B+8.2% | $1.3B+16.6% | $1.11B-3.6% | $1.16B-2.6% | ||
| $4.59M-46.8% | $8.63M-33.3% | $12.94M+8.7% | $11.91M-3.6% | ||
| $1.16M-30.7% | $1.67M-16.7% | $2.01M-23.2% | $2.61M-43.8% | ||
| $59.94M-23.8% | $78.63M+28.4% | $61.24M-2.2% | $62.61M-2.4% | ||
| $96.44M-22.3% | $124.07M+75.2% | $70.8M-12.8% | $81.22M-11.0% | ||
| 125M+160,156% | 78K+6.8% | 73K+1.4% | 72K+1.4% | ||
| -$377.63M+14.9% | -$443.98M+5.2% | -$468.12M-18.9% | -$393.72M-10.2% | ||
| $1.31B+11.4% | $1.18B+12.6% | $1.04B-2.9% | $1.08B-1.9% | ||
| $1.41B+8.2% | $1.3B+16.6% | $1.11B-3.6% | $1.16B-2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Veracyte cover its short-term obligations?
- Its current ratio is 9.31 — current assets exceed current liabilities.
- Where does Veracyte's balance sheet data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.